The impact of lipid-lowering medications on coronary artery plaque characteristics

Atherosclerosis is the predominant cause of coronary artery disease. The last several decades have witnessed significant advances in lipid-lowering therapies, which comprise a central component of atherosclerotic cardiovascular disease prevention. In addition to cardiovascular risk reduction with dy...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Vishnu Priya Pulipati, Francis J. Alenghat
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Atherosclerosis Plaque Prevention Therapy Lipids Cardiovascular disease Diseases of the circulatory (Cardiovascular) system RC666-701 Public aspects of medicine RA1-1270
Acceso en línea:	https://doaj.org/article/7f0b4c91947a49e98adcdcd27ed300e5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:7f0b4c91947a49e98adcdcd27ed300e5
record_format	dspace
spelling	oai:doaj.org-article:7f0b4c91947a49e98adcdcd27ed300e52021-11-24T04:34:56ZThe impact of lipid-lowering medications on coronary artery plaque characteristics2666-667710.1016/j.ajpc.2021.100294https://doaj.org/article/7f0b4c91947a49e98adcdcd27ed300e52021-12-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666667721001495https://doaj.org/toc/2666-6677Atherosclerosis is the predominant cause of coronary artery disease. The last several decades have witnessed significant advances in lipid-lowering therapies, which comprise a central component of atherosclerotic cardiovascular disease prevention. In addition to cardiovascular risk reduction with dyslipidemia management, some lipid-based therapies show promise at the level of the atherosclerotic plaque itself through mechanisms governing lipid accumulation, plaque stability, local inflammation, endothelial dysfunction, and thrombogenicity. The capacity of lipid-lowering therapies to modify atherosclerotic plaque burden, size, composition, and vulnerability should correlate with their ability to reduce disease progression. This review discusses plaque characteristics, diagnostic modalities to evaluate these characteristics, and how they are altered by current and emerging lipid-lowering therapies, all in human coronary artery disease.Vishnu Priya PulipatiFrancis J. AlenghatElsevierarticleAtherosclerosisPlaquePreventionTherapyLipidsCardiovascular diseaseDiseases of the circulatory (Cardiovascular) systemRC666-701Public aspects of medicineRA1-1270ENAmerican Journal of Preventive Cardiology, Vol 8, Iss , Pp 100294- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Atherosclerosis Plaque Prevention Therapy Lipids Cardiovascular disease Diseases of the circulatory (Cardiovascular) system RC666-701 Public aspects of medicine RA1-1270
spellingShingle	Atherosclerosis Plaque Prevention Therapy Lipids Cardiovascular disease Diseases of the circulatory (Cardiovascular) system RC666-701 Public aspects of medicine RA1-1270 Vishnu Priya Pulipati Francis J. Alenghat The impact of lipid-lowering medications on coronary artery plaque characteristics
description	Atherosclerosis is the predominant cause of coronary artery disease. The last several decades have witnessed significant advances in lipid-lowering therapies, which comprise a central component of atherosclerotic cardiovascular disease prevention. In addition to cardiovascular risk reduction with dyslipidemia management, some lipid-based therapies show promise at the level of the atherosclerotic plaque itself through mechanisms governing lipid accumulation, plaque stability, local inflammation, endothelial dysfunction, and thrombogenicity. The capacity of lipid-lowering therapies to modify atherosclerotic plaque burden, size, composition, and vulnerability should correlate with their ability to reduce disease progression. This review discusses plaque characteristics, diagnostic modalities to evaluate these characteristics, and how they are altered by current and emerging lipid-lowering therapies, all in human coronary artery disease.
format	article
author	Vishnu Priya Pulipati Francis J. Alenghat
author_facet	Vishnu Priya Pulipati Francis J. Alenghat
author_sort	Vishnu Priya Pulipati
title	The impact of lipid-lowering medications on coronary artery plaque characteristics
title_short	The impact of lipid-lowering medications on coronary artery plaque characteristics
title_full	The impact of lipid-lowering medications on coronary artery plaque characteristics
title_fullStr	The impact of lipid-lowering medications on coronary artery plaque characteristics
title_full_unstemmed	The impact of lipid-lowering medications on coronary artery plaque characteristics
title_sort	impact of lipid-lowering medications on coronary artery plaque characteristics
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/7f0b4c91947a49e98adcdcd27ed300e5
work_keys_str_mv	AT vishnupriyapulipati theimpactoflipidloweringmedicationsoncoronaryarteryplaquecharacteristics AT francisjalenghat theimpactoflipidloweringmedicationsoncoronaryarteryplaquecharacteristics AT vishnupriyapulipati impactoflipidloweringmedicationsoncoronaryarteryplaquecharacteristics AT francisjalenghat impactoflipidloweringmedicationsoncoronaryarteryplaquecharacteristics
_version_	1718415920849747968

The impact of lipid-lowering medications on coronary artery plaque characteristics

Ejemplares similares